Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Preetesh Jain, Sairah Ahmed, Chi Young Ok, Ranjit Nair, Ahmed Fetooh, Holly Hill, Tatiana Vasilyeva, Ajlan Al Zaki, Anastasiya Evdokimova, Viktor Smirnov, Tolina Turova, Ilya Anosov, Lizzie Sheehan, Selvi Thirumurthi, Anita Deswal, Cezar Iliescu, Vinh Nguyen, Joel Thomas, Naveen Garg, Dhruv Kumar, Cameron Noorbakhsh, Sa Wang, Keyur Patel, Francisco Vega, L. Jeffrey Medeiros, Guilin Tang, Partow Kebriaei, Neeraj Saini, Susan Wu, Bouthaina Dabaja, Nikkita Kotlov, Michael Goldberg, Cara Haymaker, Christopher Flowers, Sattva Neelapu, Michael Wang
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417007994